肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

EUR J Cancer：FOLFOXIRI联合贝伐单抗治疗肝脏限制性转移性结直肠癌的疗效观察

2017-12-31 MedSci MedSci原创

转移性结直肠癌FOLFOXIRI贝伐单抗
关注

二次切除是治愈转移性结直肠癌（mCRC）中不能切除的肝脏限制性亚组患者的一个机会。肿瘤治疗的双重目标包括诱导肿瘤组织缩小和预防疾病的复发。FOLFOXIRI（亚叶酸，5-氟尿嘧啶，奥沙利铂和伊立替康）目前仍为一种标准化疗方案，在此研究人员分析评估了FOLFOXIRI联合贝伐单抗对肝脏限制性转移性结直肠癌的疗效，并调查了该治疗方案是否可以逆转高危患者的不良预后。

二次切除是治愈转移性结直肠癌（mCRC）中不能切除的肝脏限制性亚组患者的一个机会。肿瘤治疗的双重目标包括诱导肿瘤组织缩小和预防疾病的复发。FOLFOXIRI（亚叶酸，5-氟尿嘧啶，奥沙利铂和伊立替康）目前仍为一种标准化疗方案，在此研究人员分析评估了FOLFOXIRI联合贝伐单抗对肝脏限制性转移性结直肠癌的疗效，并调查了该治疗方案是否可以逆转高危患者的不良预后。

在541例患者中，有205例（37.9%）为肝脏限制性mCRC。74名患者（36.1%）接受了转移瘤的R0或R1切除。17名患者（8.3%）接受了R2切除。在单变量和多变量分析中，相比于其他患者，R0 / R1切除的患者具有显著延长的中位无进展生存期（PFS）（18.1 vs 10.7个月，HR：0.48 [0.35-0.66]，p <0.001）和总生存期（OS）（44.3 vs 24.4个月，HR：0.32 [0.22-0.48]，P <0.001）。R0切除的患者的5年PFS和OS率分别为12%和43%。

综上所述，综合长期试验结果和预后因素，FOLFOXIRI联合贝伐单抗治疗肝脏限制性转移性结直肠癌是安全有效的。 

原始出处：

Cremolini, Chiara, et al. "Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest." European Journal of Cancer 2017 73: 74-84. doi.org/10.1016/j.ejca.

本文系梅斯医学（MedSci）原创编译整理，转载需授权

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1386341, encodeId=fe2e1386341ef, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jan 02 12:06:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453060, encodeId=999f14530606c, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Tue Jan 02 12:06:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455451, encodeId=1937145545196, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Jan 02 12:06:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477011, encodeId=5feb14e701136, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Tue Jan 02 12:06:00 CST 2018, time=2018-01-02, status=1, ipAttribution=)]
    2018-01-02 1249842em09(暂无昵称)

    #转移性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1386341, encodeId=fe2e1386341ef, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jan 02 12:06:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453060, encodeId=999f14530606c, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Tue Jan 02 12:06:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455451, encodeId=1937145545196, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Jan 02 12:06:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477011, encodeId=5feb14e701136, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Tue Jan 02 12:06:00 CST 2018, time=2018-01-02, status=1, ipAttribution=)]
    2018-01-02 crystal0564

    #结直肠#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1386341, encodeId=fe2e1386341ef, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jan 02 12:06:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453060, encodeId=999f14530606c, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Tue Jan 02 12:06:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455451, encodeId=1937145545196, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Jan 02 12:06:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477011, encodeId=5feb14e701136, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Tue Jan 02 12:06:00 CST 2018, time=2018-01-02, status=1, ipAttribution=)]
    2018-01-02 医者仁心

    #FOLFOX#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1386341, encodeId=fe2e1386341ef, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jan 02 12:06:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453060, encodeId=999f14530606c, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Tue Jan 02 12:06:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455451, encodeId=1937145545196, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Jan 02 12:06:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477011, encodeId=5feb14e701136, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Tue Jan 02 12:06:00 CST 2018, time=2018-01-02, status=1, ipAttribution=)]
    2018-01-02 sunrural_42825359

    #贝伐#

    0

相关资讯

JCO：Trifluridine/Tipiracil治疗亚洲人群转移性结直肠癌

Trifluridine/Tipiracil（TAS-102）在一项日本的Ⅱ期临床试验中已证明对转移性结直肠癌患者有效。JCO近期报道了Trifluridine/Tipiracil在生物治疗暴露或未暴露的亚洲转移性结直肠癌患者中的有效性及安全性。

CLIN CANCER RES：低剂量环磷酰胺诱导抗肿瘤T细胞反应且与转移性结直肠癌患者预后有关

抗肿瘤T细胞反应可以控制肿瘤，但是免疫抑制机制会影响其功能。Treg细胞在转移性结直肠癌中发挥的作用尚未知。之前有研究证明Treg缺失可以增强结直肠癌特异性效应T细胞反应。在动物模型及人体试验中证实低剂量环磷酰胺可以靶向Treg，但是环磷酰胺对转移性结直肠癌的影响尚不清楚。CLIN CANCER RES近期发表了一篇文章研究这一问题。

2017 加拿大共识声明：原发肿瘤位置在转移性结直肠癌的治疗的预期作用

最近公布的数据显示了原发肿瘤位置对可用生物疗法治疗的转移结直肠癌的预测价值。本文主要总结了基于原发肿瘤的位置治疗转移性结直肠癌的相关内容并提出指导建议。

EUR J Cancer：卡培他滨联合贝伐单抗在转移性结直肠癌维持治疗中的成本效益分析

成本效益分析是通过比较项目的全部成本和效益来评估项目价值的一种方法，成本效益分析作为一种经济决策方法已经用于医疗领域。就转移性结直肠癌患者的无进展生存期而言，在6个疗程的卡培他滨、奥沙利铂和贝伐单抗的一线治疗后，卡培他滨联合贝伐单抗（CAP-B）的维持治疗能够起到很好的疗效。这篇文献中，荷兰研究者们评估了CAP-B的成本效益。

ANN ONCOL：MAPK信号通路基因改变对接受一线FOLFIRI联合贝伐单抗治疗的转移性结直肠癌患者预后的影响

MAPK酶1（MKNK1）位于RAS/RAF/ERK和MAP3K1/MKK/p38信号通路的下游。磷酸化MKNK1调节翻译起始因子4E的功能。翻译起始因子4E是转录控制的关键因素，其表达在转移性结直肠癌患者中升高。临床前数据表明MKNK1上调血管生成因子促进血管生成。ANN ONCOL近期发表了一篇文章，研究MKNK1基因改变是否可以预测接受一线FOLFIRI和贝伐单抗治疗的转移性结直肠癌患者的预

必看：肠癌大咖共话转移性结直肠癌靶向治疗热点

2017年10月27-29日，第二届中国抗癌协会肿瘤靶向治疗专业委员会年会在湖北武汉成功召开，肿瘤靶向治疗开展得如火如荼，其进展日新月异，本次大会特别邀请国内著名的肿瘤学基础和临床专家就相关领域最新进展进行精彩的专题报告，深入探讨前沿理论和热点问题。肿瘤资讯有幸邀请到张克亮、袁瑛、曾珊、张涛、殷先利、刘莺等教授，就转移性结直肠癌整体治疗策略及靶向治疗相关热点问题进行点评。